SELE and acute myeloid leukemia: Selectin E upregulates both the WNT and sonic hedgehog pathways in AML resulting in promoting AML blast cells survival so by targeting those molecules through the addition of GMI-1271 (uproleselan) to the AML initial therapy protocol a better outcome may be achieved [106–109].